In particular, hs-cTnT is frequently used for risk stratification [14], with the assumption that the risk of life-threatening arrhythmia decreases after peak levels of hs-cTnT (hs-cTnTpeak) have been reached. This evidence concerns the gene TNNT2 and cardiac arrhythmia.